What do systematic reviews say?

Class I antiarrhythmics vs control

The review found no eligible studies for this question.

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Class I antiarrhythmics vs control

The review found no eligible studies for this question.

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Class I antiarrhythmics vs control

The review found no eligible studies for this question.

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Class III antiarrhythmics vs control

It is very uncertain whether class III antiarrhythmics changes adverse events: thromboembolic events compared with control (very low certainty).

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  Peto OR 0.96 [0.06, 15.5]
  1 study · 212 participants
  Very low

Class III antiarrhythmics vs control

The review found no eligible studies for this question.

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Class III antiarrhythmics vs control

The review found no eligible studies for this question.

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Class I antiarrhythmics vs control

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 participants
  GRADE not reported

Class III antiarrhythmics vs control

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 participants
  GRADE not reported

Class I and/or III antiarrhythmics vs control

It is very uncertain whether class I and/or III antiarrhythmics changes adverse events: thromboembolic events compared with control (very low certainty).

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  Peto OR 0.96 [0.06, 15.5]
  1 study · 212 participants
  Very low

Class I and/or III antiarrhythmics vs control

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 participants
  GRADE not reported

Class I and/or III antiarrhythmics vs control

The review found no eligible studies for this question.

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Class I and/or III antiarrhythmics vs control

• Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 participants
  GRADE not reported